Add this topic to your myFT Digest for news straight to your inbox
Pascal Soriot sought to deliver a research-led renaissance at AstraZeneca
Drugmaker boosted by strong performance of new treatments for cancer and heart disease
Some investors and analysts still unconvinced UK company was right to resist approach
Sales growth and drug approvals accelerate in world’s second-largest market
Adviser ISS raises concerns over bonus targets and disclosure
Soriot forecasts sales growth above 20% as he unveils collaborations with tech groups
But questions remain about drugmaker’s longer term prospects
Drugmaker looks to shrug off Mystic blow with upbeat results for lung cancer drugs
Soriot says pharma group will ‘wait to see’ before key decisions on further UK investment
Flagship lung cancer treatment failed to show benefits hoped for by pharma group
About £10bn is wiped off value of company amid rumours of Soriot’s departure
Chief executive Pascal Soriot should stay and finish his work
Chief executive to present earnings on July 27, scotching rumours of move to rival Teva
One can see why chief executive Pascal Soriot might be tempted to move on
Israeli newspaper says Pascal Soriot plans to leave drugmaker to join Teva
Results from eagerly awaited Mystic immunotherapy trial expected within weeks
Pressure to find new revenue increases as pharma group enters pivotal period
World’s biggest oncology summit focuses on drugs that boost body’s ability to fight
Much will depend on drug trial data readouts in the second half of this year
International Edition